Payment overview · 2025
General Payments
$976.73
39 reported records · 19 companies
Healthcare provider profile · identity verified
Nirupama Vemuri, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Nephrology · PORTERVILLE, CA · NPI 1659303980
Verified facts
What the public records show
CMS Open Payments records show Nirupama Vemuri, MD received $976.73 in general payments during 2025 across 39 reported records.
Amgen Inc. accounted for 22.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Gemtesa, Jardiance, Kerendia, Mounjaro, Prolia, Trelegy Ellipta.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Prolia by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 272 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Lokelma by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Kerendia by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 113 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 154 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 165 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 445 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 365 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Paxlovid by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $220.67 | 22.6% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $130.33 | 13.3% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $87.78 | 9.0% | 3 | 2025 |
| Calliditas Therapeutics US Inc. | Unresolved — no canonical attribution shown | $71.26 | 7.3% | 4 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $58.36 | 6.0% | 3 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $56.26 | 5.8% | 3 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $49.02 | 5.0% | 3 | 2025 |
| Travere Therapeutics, Inc. | Unresolved — no canonical attribution shown | $48.10 | 4.9% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $39.53 | 4.0% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $28.85 | 3.0% | 2 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $24.47 | 2.5% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $24.23 | 2.5% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $24.14 | 2.5% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $22.15 | 2.3% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $22.02 | 2.2% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $19.84 | 2.0% | 1 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $18.80 | 1.9% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $16.14 | 1.6% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.78 | 1.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $801.73 | 38 |
| Consulting Fee | $175.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $175.00 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $116.38 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $87.78 | 3 | 2025 |
Source payment records
|
|||||
| TARPEYO Normalized: tarpeyo |
Drug | Calliditas Therapeutics US Inc. | $71.26 | 4 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $58.36 | 3 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $56.26 | 3 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $49.02 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $39.53 | 2 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $32.70 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $28.85 | 2 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $24.47 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $24.23 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $24.14 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $22.15 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $22.15 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $22.15 | 1 | 2025 |
Source payment records
|
|||||
| JYNARQUE Normalized: jynarque |
Drug | Otsuka America Pharmaceutical, Inc. | $22.02 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $19.84 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $18.80 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $15.00 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $14.78 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $13.95 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $13.95 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $12.97 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $12.97 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 272 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 154 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 48 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 165 | exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 113 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
83 | 18 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
272 | 56 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
48 | 12 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
113 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
154 | 36 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
165 | 32 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
71 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
445 | 85 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
78 | 16 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
365 | 42 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
19 | 19 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1709 | 411 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1223 | 241 |
| Amlodipine Besylate | Amlodipine Besylate | 674 | 195 |
| Furosemide | Furosemide | 630 | 150 |
| Gabapentin | Gabapentin | 606 | 117 |
| Pantoprazole Sodium | Pantoprazole Sodium | 567 | 120 |
| Lisinopril | Lisinopril | 549 | 132 |
| Metoprolol Succinate | Metoprolol Succinate | 526 | 149 |
| Metformin Hcl | Metformin Hcl | 520 | 132 |
| Sertraline Hcl | Sertraline Hcl | 513 | 96 |
| Ozempic | Semaglutide | 445 | 85 |
| Allopurinol | Allopurinol | 441 | 95 |
| Calcitriol | Calcitriol | 437 | 113 |
| Losartan Potassium | Losartan Potassium | 388 | 103 |
| Tamsulosin Hcl | Tamsulosin Hcl | 368 | 89 |
| Eliquis | Apixaban | 365 | 42 |
| Omeprazole | Omeprazole | 352 | 84 |
| Hydralazine Hcl | Hydralazine Hcl | 298 | 91 |
| Januvia | Sitagliptin Phosphate | 294 | 47 |
| Glipizide | Glipizide | 292 | 75 |
| Simvastatin | Simvastatin | 283 | 70 |
| Valsartan | Valsartan | 278 | 73 |
| Farxiga | Dapagliflozin Propanediol | 272 | 56 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 269 | 87 |
| Paroxetine Hcl | Paroxetine Hcl | 268 | 41 |
| Memantine Hcl | Memantine Hcl | 261 | 28 |
| Montelukast Sodium | Montelukast Sodium | 246 | 68 |
| Spironolactone | Spironolactone | 244 | 43 |
| Benazepril Hcl | Benazepril Hcl | 242 | 70 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 239 | 76 |
| Doxazosin Mesylate | Doxazosin Mesylate | 216 | 59 |
| Hydrochlorothiazide | Hydrochlorothiazide | 214 | 68 |
| Alprazolam | Alprazolam | 204 | 54 |
| Fenofibrate | Fenofibrate | 201 | 58 |
| Duloxetine Hcl | Duloxetine Hcl | 196 | 33 |
| Donepezil Hcl | Donepezil Hcl | 193 | 19 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 190 | 43 |
| Metoprolol Tartrate | Metoprolol Tartrate | 188 | 45 |
| Trazodone Hcl | Trazodone Hcl | 184 | 31 |
| Carvedilol | Carvedilol | 178 | 41 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 175 | 139 |
| Mounjaro | Tirzepatide | 165 | 32 |
| Clonidine Hcl | Clonidine Hcl | 164 | 53 |
| Entresto | Sacubitril/Valsartan | 164 | 23 |
| Alendronate Sodium | Alendronate Sodium | 162 | 52 |
| Escitalopram Oxalate | Escitalopram Oxalate | 158 | 24 |
| Potassium Chloride | Potassium Chloride | 158 | 38 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 155 | 41 |
| Jardiance | Empagliflozin | 154 | 36 |
| Nifedipine Er | Nifedipine | 154 | 29 |
| Diclofenac Sodium | Diclofenac Sodium | 153 | 40 |
| Finasteride | Finasteride | 153 | 43 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 152 | 114 |
| Glimepiride | Glimepiride | 150 | 35 |
| Pravastatin Sodium | Pravastatin Sodium | 144 | 42 |
| Celecoxib | Celecoxib | 139 | 38 |
| Clopidogrel | Clopidogrel Bisulfate | 139 | 35 |
| Amiodarone Hcl | Amiodarone Hcl | 136 | 13 |
| Cinacalcet Hcl | Cinacalcet Hcl | 135 | 29 |
| Propranolol Hcl | Propranolol Hcl | 132 | 29 |
| Baclofen | Baclofen | 131 | 34 |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 128 | 33 |
| Bumetanide | Bumetanide | 123 | 25 |
| Calcium Acetate | Calcium Acetate | 121 | 29 |
| Azithromycin | Azithromycin | 120 | 102 |
| Amoxicillin | Amoxicillin | 119 | 108 |
| Tramadol Hcl | Tramadol Hcl | 115 | 48 |
| Divalproex Sodium | Divalproex Sodium | 113 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 113 | 23 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 112 | 29 |
| Midodrine Hcl | Midodrine Hcl | 101 | 24 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 101 | 69 |
| Lorazepam | Lorazepam | 99 | 20 |
| Citalopram Hbr | Citalopram Hydrobromide | 97 | suppressed |
| Pregabalin | Pregabalin | 95 | 16 |
| Buspirone Hcl | Buspirone Hcl | 94 | 11 |
| Sevelamer Carbonate | Sevelamer Carbonate | 93 | 22 |
| Meloxicam | Meloxicam | 92 | 23 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 88 | suppressed |
| Ezetimibe | Ezetimibe | 87 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 85 | 25 |
| Oxybutynin Chloride | Oxybutynin Chloride | 85 | 17 |
| Myrbetriq | Mirabegron | 83 | 18 |
| Fluticasone Propionate | Fluticasone Propionate | 82 | 33 |
| Prednisone | Prednisone | 82 | 51 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 79 | 26 |
| Ibuprofen | Ibuprofen | 79 | 26 |
| Rybelsus | Semaglutide | 78 | 16 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 77 | 18 |
| Meclizine Hcl | Meclizine Hcl | 77 | 36 |
| Ropinirole Hcl | Ropinirole Hcl | 77 | 19 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 76 | 21 |
| Breo Ellipta | Fluticasone/Vilanterol | 73 | 19 |
| Cephalexin | Cephalexin | 73 | 60 |
| Bupropion Xl | Bupropion Hcl | 72 | 13 |
| Ondansetron Odt | Ondansetron | 72 | 29 |
| Tradjenta | Linagliptin | 72 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 71 | 22 |
| Trulicity | Dulaglutide | 71 | 15 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 70 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 70 | 19 |
| Nicardipine Hcl | Nicardipine Hcl | 69 | 12 |
| Veltassa | Patiromer Calcium Sorbitex | 69 | 23 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 64 | 37 |
| Famotidine | Famotidine | 62 | 19 |
| Atenolol | Atenolol | 59 | 18 |
| Colchicine | Colchicine | 58 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 58 | 16 |
| Mupirocin | Mupirocin | 57 | 40 |
| Nystatin | Nystatin | 57 | 29 |
| Amitriptyline Hcl | Amitriptyline Hcl | 55 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 55 | 26 |
| Memantine Hcl Er | Memantine Hcl | 55 | suppressed |
| Amantadine | Amantadine Hcl | 53 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 51 | suppressed |
| Glipizide Er | Glipizide | 50 | 14 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 50 | 15 |
| Paricalcitol | Paricalcitol | 49 | suppressed |
| Sulfasalazine | Sulfasalazine | 49 | suppressed |
| Kerendia | Finerenone | 48 | 12 |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 47 | 13 |
| Lactulose | Lactulose | 46 | 20 |
| Methocarbamol | Methocarbamol | 46 | suppressed |
| Chlorthalidone | Chlorthalidone | 45 | 12 |
| Ketoconazole | Ketoconazole | 45 | 22 |
| Sodium Polystyrene Sulfonate | Sodium Polystyrene Sulfonate | 43 | 12 |
| Pioglitazone Hcl | Pioglitazone Hcl | 42 | 12 |
| Azelastine Hcl | Azelastine Hcl | 41 | 21 |
| Venlafaxine Hcl | Venlafaxine Hcl | 41 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 40 | suppressed |
| Lovastatin | Lovastatin | 40 | 11 |
| Velphoro | Sucroferric Oxyhydroxide | 40 | 12 |
| Fluconazole | Fluconazole | 39 | 17 |
| Sucralfate | Sucralfate | 39 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 39 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 39 | 11 |
| Droplet Pen Needle | Pen Needle, Diabetic | 38 | 15 |
| Symbicort | Budesonide/Formoterol Fumarate | 38 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 37 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 37 | suppressed |
| Novolog Flexpen | Insulin Aspart | 36 | suppressed |
| Ursodiol | Ursodiol | 36 | suppressed |
| Linzess | Linaclotide | 35 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 34 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 33 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 32 | suppressed |
| Levetiracetam | Levetiracetam | 32 | suppressed |
| Temazepam | Temazepam | 32 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 31 | 21 |
| Nortriptyline Hcl | Nortriptyline Hcl | 30 | suppressed |
| Premarin | Estrogens, Conjugated | 30 | suppressed |
| Cholestyramine Light | Cholestyramine | 29 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 28 | 21 |
| Tresiba Flextouch U-100 | Insulin Degludec | 28 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 27 | suppressed |
| Gemtesa | Vibegron | 27 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | 11 |
| Levofloxacin | Levofloxacin | 26 | 24 |
| Albuterol Sulfate | Albuterol Sulfate | 25 | suppressed |
| Aripiprazole | Aripiprazole | 25 | suppressed |
| Estradiol | Estradiol | 25 | 11 |
| Ofloxacin | Ofloxacin | 25 | 22 |
| Potassium Citrate Er | Potassium Citrate | 25 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 25 | suppressed |
| Xarelto | Rivaroxaban | 25 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 24 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 24 | 11 |
| Tresiba Flextouch U-200 | Insulin Degludec | 24 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 23 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 23 | suppressed |
| Ramipril | Ramipril | 23 | suppressed |
| Lidocaine | Lidocaine | 22 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 22 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 22 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 22 | 11 |
| Edarbyclor | Azilsartan Med/Chlorthalidone | 21 | suppressed |
| Mirtazapine | Mirtazapine | 21 | suppressed |
| Naproxen | Naproxen | 21 | 13 |
| Ibandronate Sodium | Ibandronate Sodium | 20 | suppressed |
| Loperamide | Loperamide Hcl | 20 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 20 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 19 | 12 |
| Enulose | Lactulose | 19 | suppressed |
| Febuxostat | Febuxostat | 19 | suppressed |
| Irbesartan | Irbesartan | 19 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 19 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 19 | 19 |
| Lokelma | Sodium Zirconium Cyclosilicate | 18 | suppressed |
| Xultophy 100-3.6 | Insulin Degludec/Liraglutide | 18 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 17 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 17 | suppressed |
| Acyclovir | Acyclovir | 16 | suppressed |
| Clonidine | Clonidine | 16 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Minoxidil | Minoxidil | 16 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 16 | suppressed |
| Ranolazine Er | Ranolazine | 16 | suppressed |
| Roflumilast | Roflumilast | 16 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 16 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 16 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 15 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 15 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 15 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 15 | suppressed |
| Klor-Con 10 | Potassium Chloride | 15 | suppressed |
| Vascepa | Icosapent Ethyl | 15 | suppressed |
| Belsomra | Suvorexant | 14 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 14 | suppressed |
| Constulose | Lactulose | 14 | suppressed |
| Edarbi | Azilsartan Medoxomil | 14 | suppressed |
| Fluocinonide | Fluocinonide | 14 | suppressed |
| Ibu | Ibuprofen | 14 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 14 | suppressed |
| Prolia | Denosumab | 14 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 14 | suppressed |
| Verapamil Er | Verapamil Hcl | 14 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 14 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 13 | 11 |
| Cilostazol | Cilostazol | 13 | suppressed |
| Creon | Lipase/Protease/Amylase | 13 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 13 | 13 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 12 | suppressed |
| Cefixime | Cefixime | 12 | suppressed |
| Clonazepam | Clonazepam | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 12 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 12 | 12 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 12 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 12 | 12 |
| Retacrit | Epoetin Alfa-Epbx | 12 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 11 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 11 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 11 | suppressed |
| Synthroid | Levothyroxine Sodium | 11 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $976.73 · 39 records | Amgen Inc. | ABRYSVO, ACCRUFER, AREXVY, CAPVAXIVE, COMIRNATY, FARXIGA, FREESTYLE LIBRE 3, Flucelvax, GEMTESA, IBSRELA, JARDIANCE, JYNARQUE, KRYSTEXXA, Kerendia, MOUNJARO, OTEZLA, PREVNAR 20, PROLIA, REPATHA, TARPEYO, TRELEGY ELLIPTA, ULTOMIRIS, VOQUEZNA, Veozah, ZEPBOUND | 15 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error